Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS)

Gossamer Bio, Inc. (NASDAQ:GOSS) was the target of unusually large options trading activity on Monday. Investors purchased 23,621 call options on the stock. This represents an increase of approximately 882% compared to the typical daily volume of 2,406 call options.

Institutional Trading of Gossamer Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC grew its holdings in Gossamer Bio by 24.6% during the 1st quarter. Acadian Asset Management LLC now owns 6,358,113 shares of the company’s stock worth $6,991,000 after acquiring an additional 1,253,353 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Gossamer Bio by 720.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after purchasing an additional 825,047 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new stake in Gossamer Bio in the first quarter worth approximately $387,000. ProShare Advisors LLC acquired a new position in Gossamer Bio in the second quarter valued at approximately $48,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Gossamer Bio in the second quarter valued at approximately $53,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on GOSS shares. Wall Street Zen raised shares of Gossamer Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Gossamer Bio in a report on Thursday, September 11th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Gossamer Bio Stock Performance

Shares of NASDAQ:GOSS opened at $3.79 on Tuesday. The firm has a market cap of $877.23 million, a PE ratio of -5.49 and a beta of 1.92. Gossamer Bio has a 52 week low of $0.76 and a 52 week high of $3.87. The firm’s fifty day moving average is $2.78 and its 200-day moving average is $2.27.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%.The company had revenue of $13.29 million for the quarter, compared to the consensus estimate of $6.32 million. Sell-side analysts forecast that Gossamer Bio will post -0.28 EPS for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.